A Phase I Open Label Study to Assess the Single Dose Pharmacokinetics and Safety of Sublingual Administration of Tablets and Medicated Drops of Plant Cannabis Extract
Latest Information Update: 13 Dec 2022
At a glance
- Drugs BOL DP o 04 (Primary) ; BOL DP o 04 (Primary)
- Indications Diabetic neuropathies; Pain
- Focus Pharmacokinetics
- Sponsors BOL Pharma
- 07 Dec 2022 Status changed from active, no longer recruiting to completed.
- 13 Sep 2022 Planned number of patients changed from 58 to 90.
- 13 Sep 2022 Planned End Date changed from 15 Dec 2021 to 31 Dec 2022.